Healthcare
Live Price
Offline$0.55
-3.51% today
1Y Change
+0.89%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vaxart, Inc. (VXRT) is a Healthcare stock with a market cap of $180.00M and listed on NASDAQ. The stock last traded around $0.55 and up 0.9% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +726.7%, EPS growth of +150.0%, a dividend yield of 0.0%. What stands out right now is revenue +726.7%, EPS +150.0%, free cash flow +116.7% with operating margin 7.6% and ROIC 13.2%. Valuation is more restrained than many high-expectation growth names at P/E 10.7 and price/sales 0.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VXRT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VXRT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VXRT Max Drawdown
-46.43%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VXRT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$892.0K
+733.6% YoY
FY Net Income
-$70.5M
+34.6% YoY
Free Cash Flow
-$65.0M
+37.7% YoY
Revenue Growth
+726.7%
EPS Growth
+150.0%
Gross Margin
90.4%
Net Margin
6.9%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 237M | 29M | 7M | 107K | 892K |
| Gross Profit | 237M | 29M | 3M | 107K | -48M |
| Operating Income | 18M | -66M | -83M | -115M | -73M |
| EBITDA | 28M | -55M | -72M | -101M | -66M |
| Net Income | 16M | -67M | -82M | -108M | -70M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 54M | 25M | 35M | 44M | 144M |
| Total Assets | 186M | 166M | 92M | 154M | 221M |
| Total Liabilities | 98M | 107M | 34M | 43M | 34M |
| Shareholder Equity | 88M | 59M | 58M | 111M | 188M |
| Total Debt | 9M | 23M | 27M | 27M | 25M |
| Net Debt | -45M | -2M | -8M | -17M | -119M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
60M
+36.9% YoY
Capital Expenditures
5M
+46.3% YoY
Free Cash Flow
65M
+37.7% YoY
Key ratios
Gross Margin
90.4%
Operating Margin
7.6%
Net Margin
6.9%
ROE
33.8%
Debt / Equity
0.10x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.